Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics


KSQ® Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present new data from its USP1 inhibitor program at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) taking place virtually October 24-25, 2020. Preclinical data on the company's USP1 inhibitor program will be featured as part of a plenary session highlighting late breaking and best proffered papers, and the company will also present a poster featuring data on its lead USP1 candidate, KSQ-4279.

Presentation details:

Plenary Title: "USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors."
Session Title: Plenary Session 1: Late Breaking and Best Proffered Papers
Session Date and Time: Saturday, Oct. 24, 2020, 3:05-4:35 PM CEST (9:05-10:35 AM ET)

Poster Title: "Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers."
Poster Number: 184
Session Code: 380
Poster Session Title: New Drugs
Session Date and Time: Saturday, Oct. 24, 2020

"We are pleased to present this exciting data on our industry-leading USP1 inhibitor program and our clinical candidate KSQ-4279 at this year's ENA meeting," stated Frank Stegmeier, Ph.D., Chief Scientific Officer at KSQ. "We believe USP1 inhibitors may have significant therapeutic benefit across a wide range of cancer types, in particular in combination with well-known standard-of-care therapies such as PARP inhibitors, and we're excited to present data demonstrating that potential."

The EORTC-NCI-AACR Symposium is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). The Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to learn the latest innovations in drug development, target selection, and the impact of new discoveries in molecular biology. To register for free visit www.eortc.org/ena.

About KSQ Therapeutics

KSQ® Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ's proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ® was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.KSQtx.com.


These press releases may also interest you

at 09:56
Eucon LATAM is a fully owned subsidiary of Eucon Americas, LLC, based in Atlanta, USA. Paul was announced as Regional Director when the subsidiary first opened in April 2023....

at 09:55
Saviynt, a leading provider of cloud-native identity and governance platform solutions, has launched Saviynt Knowledge Exchange to provide customers with fast access to the most comprehensive community forum in Identity. The Knowledge Exchange makes...

at 09:48
Roborock, a global leader in ultra-intelligent home robotics engineered to simplify daily life, today announced its financial results for the full year ending December 31, 2023....

at 09:45
Blueground, the largest global operator of furnished, flexible rentals for 30+ day stays, today announced that it has secured $45 million in Series D funding. The raise includes investments from new investor Susquehanna Private Equity Investments,...

at 09:45
GPT Protocol, (MEXC: GPT) (UNI: GPT), a decentralized platform at the intersection of AI and blockchain on a mission to democratize AI development through its censorship-resistant applications, is pleased to announce its upcoming participation in the...

at 09:45
Julien's Auctions today announced a series of additions to its senior...



News published on and distributed by: